Jeffrey Bluestone

Apr 09, 2020

The Parker Institute for Cancer Immunotherapy Appoints Seasoned Health Care Leader Frederic Pla as Chief Operating Officer

Feb 06, 2020

Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases

May 29, 2019

Parker Institute for Cancer Immunotherapy, JDRF and the Helmsley Charitable Trust Form Cancer and Diabetes Research Initiative

Mar 28, 2019

Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors

Mar 20, 2019

Parker Institute to Share Pancreatic Cancer Trial Results, Microbiome and Immunotherapy Research, and New CAR-T Approaches at AACR 2019

Oct 31, 2017

BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials of Treg Cell Therapies

Oct 16, 2017

Dana-Farber Cancer Institute Joins the Parker Institute for Cancer Immunotherapy

Jun 22, 2017

The Parker Institute for Cancer Immunotherapy Trains the Next Generation of Scientific Leaders in Cancer Immunotherapy

Jun 01, 2017

Parker Institute for Cancer Immunotherapy Scientists to Present Research at ASCO 2017 on IDO Pathway Inhibitors, Novel CAR-Ts and the Microbiome's Potential in Immunotherapy